Genmab raises USD 2.4m from employee warrant exercise

Employees at Genmab have exercised warrants resulting in a capital increase of DKK 15.7m (USD 2.4m).

Photo: Joost Melis / Genmab / PR

A total of 15,541 Genmab shares have been bought by the company's employees, who have exercised warrants resulting in a capital increase of DKK 15.7m (USD 2.4m), Genmab reports in a press release.

Shares with the lowest price tag were listed at DKK 466.2 per share (USD 70.67), whereas the highest price reached DKK 1,145 (USD 173.5) per share.

On Tuesday, Genmab closed 4.4 percent lower, trading at DKK 2,390 (USD 362.2).

Following the capital increase, Genmab has issued a total of 65,718,456 shares.

Genmab partner receives conditional EU approval for cancer drug

Genmab pipeline hype makes investment bank uneasy

FDA approves another Darzalex combination treatment 

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs